• Tue May 3, 2022

  AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration

  Collaboration expanded from five to seven targets and provides AbCellera the option to co-develop therapeutic programs in partnership with Empirico.

  Read More
• Wed Apr 14, 2021

  AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

  VANCOUVER, British Columbia & SAN DIEGO, April 14, 2021 — AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strategic multi-target discovery collaboration.

  Read More
• Thu Jan 9, 2020

  Empirico Announces Strategic Collaboration to Harness Human Genetics for the Discovery and Development of Novel Antisense Oligonucleotide Therapeutics

  SAN DIEGO, January 9, 2020 — Empirico Inc. announced today that it has entered into a strategic collaboration with Ionis Pharmaceuticals.

  Read More

• Fri Jan 10, 2020

  Empirico Inks Drug Target Discovery Alliance With Antisense Drug Firm Ionis

  GENOMEWEB—Empirico said on Thursday that it has formed a drug discovery alliance with antisense therapeutics firm Ionis Pharmaceuticals.

  Read More
• Thu Jan 9, 2020

  Empirico scores $660M deal with Ionis and lands a series A-2 fundraiser

  BIOWORLD—It’s a big day for privately held Empirico Inc. as it embarks on a massive combo pharma deal with Ionis Pharmaceuticals Inc. while racking up a $12.5 million series A-2 financing.

  Read More
• Thu Jan 9, 2020

  Ionis finds new partner in a young biotech and its hopeful founder

  ENDPOINTS NEWS—Omri Gottesman came to the US from the UK 10 years ago, wide-eyed like many others.

  Read More

Check back later for upcoming events.